ArticleBMC pulmonary medicine2021

Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.

Tang-Hsiu Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.